As we identified both the BCL-2 inhibitors Venetoclax and Navitoclax as strong hits at 10 nm concentrations, we asked whether combining these agents with Idasanutlin would also be potent in KMT2A-rearranged ALL. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.